Back to Search
Start Over
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: A retrospective exploratory analysis of the BALLET study
- Source :
- Oncotarget
- Publication Year :
- 2020
-
Abstract
- Introduction Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus. Results we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a statistically significant improvement in PFS. Interestingly, a similar BMI/weight decrease within the first 8 weeks of therapy identified patients at higher risk of progression. Patients and methods we performed a retrospective analysis of patients enrolled in the BALLET trial who progressed during the study. Primary end-point was progression-free survival (PFS). Secondary end-point was the identification of other predictors of response. Conclusion A >3% weight loss at EOT is associated with better outcome in mBC patients treated with everolimus. On the contrary, a significant early weight loss represents a predictor of poor survival and could therefore be used as an early negative prognostic marker. As PI3K-inhibition also converges onto mTOR, these findings might extend to patients treated with selective PI3K inhibitors and warrant further investigation.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Ballet
outcomes
BMI
Weight loss
Internal medicine
medicine
Retrospective analysis
Everolimus
business.industry
biomarkers
weight
Exploratory analysis
everolimus
medicine.disease
Metastatic breast cancer
mTOR inhibition
metastatic breast cancer
biomarker
medicine.symptom
Weight Decrease
business
Exposure duration
Research Paper
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....5e654b37ae4d5d0403509e589ec02fe0